Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04937319 IR MST · 1 trial · 1 indication
AUCinf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.
MWG was calculated as the area under the curve (AUC) for the full 24 hours expressed.
| Arm | Type | Description |
|---|---|---|
| PF-04937319 IR MST | EXPERIMENTAL | Reference formulation |
| PF-04937319 MR 1 | EXPERIMENTAL | Test MR #1 |
| PF-04937319 MR 2 | EXPERIMENTAL | Test MR #2 |
| PF-04937319 MR 3 | EXPERIMENTAL | Test MR #3 |
| Name | Type | Description |
|---|---|---|
| PF-04937319 IR MST | DRUG | Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch |
| PF-04937319 MR 1 | DRUG | Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST |
| PF-04937319 MR 2 | DRUG | Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST |
| PF-04937319 MR 3 | DRUG | Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST |
Inclusion Criteria: * Adults with type 2 diabetes, on stable background metformin therapy either alone or in combination with another oral anti-diabetic agent (OAD) excluding thiazolidinediones (TZDs) Exclusion Criteria: * Patients with cardiovascular event within 6 months of screening * Patients...
PF-04937319 IR MST is an investigational small molecule being developed by Pfizer for the treatment of Type 2 Diabetes Mellitus. It is a modified release formulation of PF-04937319, intended for oral administration. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
PF-04937319 IR MST is a small molecule being studied for Type 2 Diabetes Mellitus. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being evaluated for its effects on glucose control in adult patients with Type 2 Diabetes Mellitus.
PF-04937319 IR MST is developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Type 2 Diabetes Mellitus.
PF-04937319 IR MST is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the treatment of Type 2 Diabetes Mellitus, and its safety and efficacy have not been established.
PF-04937319 IR MST has been studied in one completed Phase 1 clinical trial, NCT02206607. This trial compared single doses of three modified release formulations of PF-04937319 with the immediate release material-sparing-tablet formulation in adults with Type 2 Diabetes Mellitus. The study enrolled 39 participants in the United States.
PF-04937319 IR MST is a specific formulation of PF-04937319, referred to as the immediate release material-sparing-tablet (IR MST) formulation. It was studied in a clinical trial comparing it with other modified release formulations of PF-04937319. The IR MST designation indicates the specific tablet formulation used in the study.